Vishvas Garg

686 total citations
48 papers, 469 citations indexed

About

Vishvas Garg is a scholar working on Rheumatology, Immunology and Economics and Econometrics. According to data from OpenAlex, Vishvas Garg has authored 48 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 12 papers in Immunology and 11 papers in Economics and Econometrics. Recurrent topics in Vishvas Garg's work include Rheumatoid Arthritis Research and Therapies (15 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Vishvas Garg is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (15 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Vishvas Garg collaborates with scholars based in United States, Austria and United Kingdom. Vishvas Garg's co-authors include Dennis W. Raisch, Martha Skup, Dennis P. West, Beatrice Nardone, Xian Shen, Daniel Aletaha, Remo Panaccione, Jasmina Kalabic, Andrew J. Epstein and Pramod Kumar Sharma and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Vishvas Garg

43 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vishvas Garg United States	13	120	107	71	65	62	48	469
Bintu Sherif United States	14	78 0.7×	156 1.5×	85 1.2×	43 0.7×	25 0.4×	37	613
Florina Constantinescu United States	12	200 1.7×	80 0.7×	23 0.3×	34 0.5×	19 0.3×	22	494
Neel Shah United States	13	114 0.9×	100 0.9×	20 0.3×	44 0.7×	21 0.3×	38	472
Diana Sun United States	11	43 0.4×	161 1.5×	29 0.4×	65 1.0×	24 0.4×	34	600
Marie‐Blanche Valnet‐Rabier France	13	50 0.4×	43 0.4×	27 0.4×	27 0.4×	86 1.4×	28	478
Sruthi Adimadhyam United States	12	50 0.4×	28 0.3×	22 0.3×	26 0.4×	26 0.4×	23	336
Arielle G. Bensimon United States	12	48 0.4×	119 1.1×	50 0.7×	123 1.9×	8 0.1×	34	543
Angela Nagel Germany	11	194 1.6×	92 0.9×	43 0.6×	16 0.2×	14 0.2×	28	528
Przemysław Holko Poland	12	38 0.3×	74 0.7×	17 0.2×	48 0.7×	10 0.2×	33	358

Countries citing papers authored by Vishvas Garg

Since Specialization

Citations

This map shows the geographic impact of Vishvas Garg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vishvas Garg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vishvas Garg more than expected).

Fields of papers citing papers by Vishvas Garg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vishvas Garg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vishvas Garg. The network helps show where Vishvas Garg may publish in the future.

Co-authorship network of co-authors of Vishvas Garg

This figure shows the co-authorship network connecting the top 25 collaborators of Vishvas Garg. A scholar is included among the top collaborators of Vishvas Garg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vishvas Garg. Vishvas Garg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirby, Joslyn S., Siwei Wang, Vishvas Garg, et al.. (2024). Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach. SHILAP Revista de lepidopterología. 6. 1200400–1200400. 2 indexed citations

Wu, Jashin J., et al.. (2023). 41279 Real-World Switch Rates of Biologics and Associated Costs in Patients With Psoriasis. Journal of the American Academy of Dermatology. 89(3). AB81–AB81.

Wu, Jashin J., et al.. (2023). Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment. 34(1). 2200869–2200869. 1 indexed citations

Strober, Bruce, Laura K. Ferris, Kristina Callis Duffin, et al.. (2023). Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal of the American Academy of Dermatology. 90(1). 82–90. 8 indexed citations

Aletaha, Daniel, Andrew J. Epstein, Martha Skup, et al.. (2019). Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. Advances in Therapy. 36(7). 1672–1683. 38 indexed citations

Marshik, Patricia L., et al.. (2018). PRS65 - ASSESSING THE IMPACT OF CONCURRENT PRESCRIPTION OPIOID USE ON ADHERENCE TO MAINTENANCE MEDICATIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A RETROSPECTIVE CLAIMS ANALYSIS. Value in Health. 21. S415–S415. 1 indexed citations

Kaeley, Gurjit S., Daryl MacCarter, Shufang Liu, et al.. (2018). Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial. Rheumatology and Therapy. 5(1). 123–134. 8 indexed citations

Srulovici, Einav, Vishvas Garg, Becca Feldman, et al.. (2018). Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study. Advances in Therapy. 35(5). 655–665. 8 indexed citations

Li, Nanxin, Keith A. Betts, Andrew Messali, Martha Skup, & Vishvas Garg. (2017). Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Clinical Therapeutics. 39(8). 1618–1627. 10 indexed citations

10.

Bosch, Filip Van den, Andrew J.K. Östör, Siegfried Wassenberg, et al.. (2017). Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. Rheumatology and Therapy. 4(1). 85–96. 24 indexed citations

11.

Aletaha, Daniel, et al.. (2017). Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. ClinicoEconomics and Outcomes Research. Volume 9. 451–458. 7 indexed citations

12.

Schmier, Jordana K., Nancy A. Nickman, Michael T. Halpern, et al.. (2017). Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical Therapeutics. 39(8). 1600–1617. 24 indexed citations

13.

Arabyat, Rasha M., Vishvas Garg, Dennis W. Raisch, & Charles L. Bennett. (2013). Fluoroquinolone-Associated Tendon-Rupture: A Summary Of Reports In The Food And Drug Administration's (Fda's) Adverse Event Reporting System. Value in Health. 16(3). A217–A217. 2 indexed citations

14.

Rosen, Alyx, Yevgeniy Balagula, Dennis W. Raisch, et al.. (2013). Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs. 25(2). 225–234. 49 indexed citations

15.

Garg, Vishvas, Dennis W. Raisch, June M. McKoy, et al.. (2013). Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Expert Opinion on Drug Safety. 12(3). 299–307. 9 indexed citations

16.

Garg, Vishvas, et al.. (2013). Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis. Prostate Cancer and Prostatic Diseases. 16(2). 193–203. 17 indexed citations

17.

Garg, Vishvas. (2012). Comparison of the Quality of Life of Type 2 Diabetes Mellitus Patients Treated with Biguanides, Thiazolidinediones and Sulphonyl ureas. Indian Journal of Pharmacy Practice. 5(1).

18.

Garg, Vishvas, Dennis W. Raisch, June M. McKoy, et al.. (2011). PCN23 IMPACT OF US FOOD AND DRUG ADMINISTRATION'S BLACK BOX WARNINGS ON ADVERSE EVENTS REPORTING RATES FOR MULTIPLE MYELOMA DRUGS. Value in Health. 14(3). A158–A159. 1 indexed citations

19.

Raisch, Dennis W., Vishvas Garg, Zaina P. Qureshi, et al.. (2011). Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opinion on Drug Safety. 10(4). 521–528. 21 indexed citations

20.

Garg, Vishvas. (2011). Noninsulin pharmacological management of type 1 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. 15(5). 5–5. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact